IDegLira for type 2 diabetes: a systematic review and meta-analysis.

Liu Y, Li X, Zheng Y, Wang X, Wang X

Endocrine28 Sept 2023Cited by 8 (Europe PMC)

PMID37768513DOI10.1007/s12020-023-03543-zPepBankPUB-37768513

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone15

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for change in HbA1c compared with control groups.
In plain wordsIn adults with type 2 diabetes, the insulin-liraglutide combination did best for HbA1c change compared with control treatments.
Peptide
Liraglutide
Outcome
DecreaseChange in HbA1c
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
change in HbA1c,
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851301
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for the percentage of patients achieving HbA1c < 7% compared with control groups.
In plain wordsIn adults with type 2 diabetes, more people reached the HbA1c target with the combination than with control treatments.
Peptide
Liraglutide
Outcome
IncreasePatients achieving HbA1c < 7%
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
percentage of patients achieving HbA1c < 7%
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851302
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for the percentage of patients achieving HbA1c < 6.5% compared with control groups.
In plain wordsIn adults with type 2 diabetes, more people reached the stricter HbA1c target with the combination than with control treatments.
Peptide
Liraglutide
Outcome
IncreasePatients achieving HbA1c < 6.5%
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
percentage of patients achieving HbA1c < 6.5%
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851303
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for achieving HbA1c < 7.0% without weight gain and without severe or blood glucose-confirmed hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, more people reached the HbA1c target with no weight gain and no serious low glucose on the combination.
Peptide
Liraglutide
Outcome
IncreaseHbA1c < 7.0% without weight gain and without severe or BG-confirmed hypoglycaemia
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
HbA1c < 7.0% without weight gain and without severe or blood glucose (BG)-confirmed hypoglycaemia episodes
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851304
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for achieving HbA1c < 6.5% without weight gain and without severe or blood glucose-confirmed hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, more people reached the stricter HbA1c target with no weight gain and no serious low glucose on the combination.
Peptide
Liraglutide
Outcome
IncreaseHbA1c < 6.5% without weight gain and without severe or BG-confirmed hypoglycaemia
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
HbA1c < 6.5% without weight gain and without severe or BG-confirmed hypoglycaemia episodes
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851305
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for change in fasting plasma glucose compared with control groups.
In plain wordsIn adults with type 2 diabetes, the combination did best for fasting glucose change compared with control treatments.
Peptide
Liraglutide
Outcome
DecreaseChange in fasting plasma glucose
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
change in fasting plasma glucose
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851306
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for change in self-measured plasma glucose compared with control groups.
In plain wordsIn adults with type 2 diabetes, the combination did best for home-measured glucose change compared with control treatments.
Peptide
Liraglutide
Outcome
DecreaseChange in self-measured plasma glucose
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
change in self-measured plasma glucose
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851307
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for change in systolic pressure compared with control groups.
In plain wordsIn adults with type 2 diabetes, the combination did best for systolic blood pressure change compared with control treatments.
Peptide
Liraglutide
Outcome
Direction not reportedChange in systolic blood pressure
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
change in systolic pressure
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851308
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira was optimal for total daily insulin dose compared with control groups.
In plain wordsIn adults with type 2 diabetes, the combination did best for total daily insulin dose compared with control treatments.
Peptide
Liraglutide
Outcome
Direction not reportedTotal daily insulin dose
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
total daily insulin dose
2 context sentences(design, population, supporting numbers)
Summary · context
Compared with the control groups, IDegLira was optimal in
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851309
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira and control groups did not differ in change in body weight.
In plain wordsIn adults with type 2 diabetes, body weight change did not differ between the combination and control treatments.
Peptide
Liraglutide
Outcome
No significant changeChange in body weight
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851310
11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, IDegLira and control groups did not differ in change in diastolic pressure.
In plain wordsIn adults with type 2 diabetes, diastolic blood pressure change did not differ between the combination and control treatments.
Peptide
Liraglutide
Outcome
No significant changeChange in diastolic blood pressure
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851311
12HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, IDegLira and control groups did not differ in severe or blood glucose-confirmed symptomatic hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, serious low glucose events did not differ between the combination and control treatments.
Peptide
Liraglutide
Outcome
No significant changeSevere or BG-confirmed symptomatic hypoglycaemia
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851312
13HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, IDegLira and control groups did not differ in nocturnal severe or blood glucose-confirmed symptomatic hypoglycaemia.
In plain wordsIn adults with type 2 diabetes, night-time serious low glucose events did not differ between the combination and control treatments.
Peptide
Liraglutide
Outcome
No significant changeNocturnal severe or BG-confirmed symptomatic hypoglycaemia
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851313
14HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, IDegLira and control groups did not differ in adverse events.
In plain wordsIn adults with type 2 diabetes, adverse events did not differ between the combination and control treatments.
Peptide
Liraglutide
Outcome
No significant changeAdverse events
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Adverse events · Whole body
Source sentences
Summary
No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851314
15HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, IDegLira and control groups did not differ in serious adverse events.
In plain wordsIn adults with type 2 diabetes, serious adverse events did not differ between the combination and control treatments.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events
Study
n = 7,773
Comparator
Control groups (pooled)
Outcome group
Adverse events · Whole body
Source sentences
Summary
No difference was found between the IDegLira and control groups in terms of change in body weight, change in diastolic pressure, severe or BG-confirmed symptomatic hypoglycaemia, nocturnal severe or BG-confirmed symptomatic hypoglycaemia, adverse events or serious adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3776851315

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.